28 October 2021 (Thursday) - Stem Cell Evidence Alert


The nice people at the Stem Cell Evidence Alert sent their update today. I won’t lie… much of it was beyond me. But some small part of it made sense, and I’d heard of quite a few of the words. And some of it is slowly going round inside my head…


Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.Shimoni, A., et al. (2021) British Journal of Haematology [record in progress].PICO SUMMARY



On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation.Campidelli, A., et al. (2021) Clinical Lymphoma, Myeloma & Leukemia [record in progress]

Treatment of Allosensitized Patients Receiving Allogeneic Transplantation.Ciurea, S., et al (2021) Blood Advances [record in progress]

Autologous and Allogeneic Hematopoietic Cell Transplantation for Diffuse Large B-cell Lymphoma-Type Richter Syndrome.Herrera, A.F. et al. (2021) Blood Advances [record in progress]

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM).Ho, M., et al. (2021) Blood Cancer Journal 11(9):158

Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma.Innoue, Y., (2021) Bone Marrow Transplantation [record in progress]

Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide.Jullien, M., et al. (2021) Cancer Medicine [record in progress]

Bone Marrow versus Peripheral Blood Graft for Haploidentical HCT with Post Transplantation Cyclophosphamide.Mehta, R. S., (2021) Transplantation and Cellular Therapy [record in progress]Planned granulocyte-colony stimulating factor adversely impacts survival after allogeneic hematopoietic cell transplantation performed with Thymoglobulin for myeloid malignancy.Orfali, N., et al. (2021) Transplantation and Cellular Therapy [record in progress]

Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia.Rocha, V., et al. (2021) Bone Marrow Transplantation [record in progress]


No comments:

Post a Comment